<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145222</url>
  </required_header>
  <id_info>
    <org_study_id>CNS 7056-004</org_study_id>
    <nct_id>NCT01145222</nct_id>
  </id_info>
  <brief_title>Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy</brief_title>
  <official_title>A Phase IIb Study Evaluating the Safety and Efficacy of Multiple Doses of CNS 7056 Compared to Midazolam in Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this dose-response study is to assess the safety and efficacy of CNS 7056
      compared with midazolam to maintain suitable sedation levels in patients undergoing
      colonoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, parallel group, dose-response study to assess the safety
      and efficacy of three dose levels of CNS 7056 compared with midazolam to maintain suitable
      sedation levels in patients undergoing colonoscopy.

      Safety assessment will include physical examinations, vital signs, ECGs, pulse oximetry
      measurements, capnography, clinical chemistry and hematology laboratory tests, routine drug
      and ethanol screening, urinalysis, pregnancy test, pain on injection using a verbal scale,
      and monitoring of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the success of the procedure, by a composite measurement of sedation level, procedure completion, alternative sedation required and if ventilation was necessary.</measure>
    <time_frame>From start of study drug injection to patient discharge (approx. 3 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety by measurement of Adverse Events.</measure>
    <time_frame>From start of study drug injection to patient discharge (approx. 3 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Sedation levels and duration.</measure>
    <time_frame>From start of study drug injection to patient discharge (approx. 3 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Procedure recall and Cognitive function.</measure>
    <time_frame>From prior to study drug injection until patient completes follow-up visit (approx. 4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of standard Pharmacokinetic parameters of CNS 7056 in human plasma.</measure>
    <time_frame>From prior to study drug injection until patient discharge (approx. 3 hours)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>A. CNS 7056</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B. CNS 7056</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C. CNS 7056</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D. Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A. CNS 7056</intervention_name>
    <description>Initial low dose plus supplemental doses as necessary.</description>
    <arm_group_label>A. CNS 7056</arm_group_label>
    <other_name>CAS No. 1001415-66-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B. CNS 7056</intervention_name>
    <description>Initial intermediate dose plus supplemental doses as necessary.</description>
    <arm_group_label>B. CNS 7056</arm_group_label>
    <other_name>CAS No. 1001415-66-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C. CNS 7056</intervention_name>
    <description>Initial high dose plus supplemental doses as necessary.</description>
    <arm_group_label>C. CNS 7056</arm_group_label>
    <other_name>CAS No. 1001415-66-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D. Midazolam</intervention_name>
    <description>Initial standardized dose plus supplemental doses as necessary.</description>
    <arm_group_label>D. Midazolam</arm_group_label>
    <other_name>CAS No. 59467-96-8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 18 to 70 years of age scheduled to undergo a standard
             colonoscopy

          -  American Society of Anesthesiologists Physical Status (ASA-PS) Score I, II, or III

          -  Weight range 55 to 130 kg inclusive

          -  BMI 18 ≤33 kg/m2

        Exclusion Criteria:

          -  Expected duration of colonoscopy &gt;30 minutes

          -  Patients with a suspected or diagnosed pathology of the lower GI tract that would add
             to the risk of colonoscopy, such as strictures or active inflammatory bowel disease

          -  ASA III patients with history of sleep apnea

          -  ASA III patients with obesity (BMI ≥30 kg/m2)

          -  Patients with evidence of uncontrolled renal, hepatic, central nervous system,
             respiratory, cardiovascular or metabolic dysfunction, or other clinically significant
             findings at screening that, in the investigator's or medical monitor's opinion, should
             exclude them from the study

          -  Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone,
             or a medical condition such that these agents are contraindicated

          -  Patients in whom management of airway is judged to be difficult due to thyro-mental
             distance ≤4 cm (&quot;short neck&quot;) or Mallampati score of 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim P. Lees, B.Sc. MedSci</last_name>
    <role>Study Director</role>
    <affiliation>Paion UK Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRI Phase I LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Associates</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <disposition_first_submitted>August 4, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 4, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 15, 2011</disposition_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jim Lees, Clinical Development Manager</name_title>
    <organization>PAION UK Ltd.</organization>
  </responsible_party>
  <keyword>CNS 7056</keyword>
  <keyword>Procedural Sedation</keyword>
  <keyword>Colonoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

